IDH1 and IDH2 mutations are frequent events in central chondrosarcoma and central and periosteal chondromas but not in other mesenchymal tumours
Royal National Orthopaedic Hospital · Royal National Orthopaedic Hospital NHS Trust · +7 more institutions
Abstract
Somatic mutations in isocitrate dehydrogenase 1 (IDH1) and IDH2 occur in gliomas and acute myeloid leukaemia (AML). Since patients with multiple enchondromas have occasionally been reported to have these conditions, we hypothesized that the same mutations would occur in cartilaginous neoplasms. Approximately 1200 mesenchymal tumours, including 220 cartilaginous tumours, 222 osteosarcomas and another ∼750 bone and soft tissue tumours, were screened for IDH1 R132 mutations, using Sequenom(®) mass spectrometry. Cartilaginous tumours and chondroblastic osteosarcomas, wild-type for IDH1 R132, were analysed for IDH2 (R172, R140) mutations. Validation was performed by capillary sequencing and restriction enzyme…
Citation impact
- FWCI
- 43.97
- Percentile
- 100%
- References
- 53
Authors
16- MFMaria Fernanda AmaryCorresponding
Royal National Orthopaedic Hospital, Royal National Orthopaedic Hospital NHS Trust, University College London
- KBKrisztián Bácsi
Royal National Orthopaedic Hospital NHS Trust, University College London
- FMFrancesca Maggiani
Royal National Orthopaedic Hospital NHS Trust, University College London
- SDStephen Damato
Royal National Orthopaedic Hospital NHS Trust, University College London
- DHDina Halai
Royal National Orthopaedic Hospital NHS Trust, University College London
Topics & keywords
- IDH2
- Isocitrate dehydrogenase
- Chondrosarcoma
- IDH1
- Mesenchymal chondrosarcoma
- Mutation
- Cancer research
- Pathology